Next Article in Journal
Anti-Metastatic and Anti-Angiogenic Effects of Curcumin Analog DK1 on Human Osteosarcoma Cells In Vitro
Next Article in Special Issue
Antibiotic Resistance Profile and Biofilm Production of Staphylococcus pseudintermedius Isolated from Dogs in Thailand
Previous Article in Journal
PESIN Conjugates for Multimodal Imaging: Can Multimerization Compensate Charge Influences on Cell Binding Properties? A Case Study
Previous Article in Special Issue
In Vitro Time-Kill of Common Ocular Pathogens with Besifloxacin Alone and in Combination with Benzalkonium Chloride
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 14
Issue 6
10.3390/ph14060533
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Beta-Lactam Resistome Expressed by Aerobic and Anaerobic Bacteria Isolated from Human Feces of Healthy Donors

by
Rosalino Vázquez-López
1,
Sandra Solano-Gálvez
2,
Diego Abelardo Álvarez-Hernández
1,3,
Jorge Alberto Ascencio-Aragón
1,
Eduardo Gómez-Conde
4,
Celia Piña-Leyva
5,
Manuel Lara-Lozano
5,
Tayde Guerrero-González
5 and
Juan Antonio González-Barrios
5,*
1
Departamento de Microbiología, Centro de Investigación en Ciencias de la Salud (CICSA) Facultad de Ciencias de la Salud Universidad Anáhuac Mexico Norte, Huixquilucan 52786, Mexico
2
Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México, Coyoacán, Ciudad de México 04510, Mexico
3
Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, Bloomsbury, London WC1E 7HT, UK
4
Laboratorio de Investigación en Inmunobiología, Facultad de Medicina, Benemérita Universidad Autónoma de Puebla (BUAP), Puebla 72420, Mexico
5
Laboratorio de Medicina Genómica, Hospital Regional “Primero de Octubre”, ISSSTE, Av. Instituto Politécnico Nacional 1669, Lindavista, Gustavo A. Madero, Ciudad de México 07300, Mexico
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2021, 14(6), 533; https://doi.org/10.3390/ph14060533
Submission received: 16 April 2021 / Revised: 18 May 2021 / Accepted: 22 May 2021 / Published: 3 June 2021
(This article belongs to the Special Issue Mechanisms of Antibiotic Action and Resistance)
Browse Figure
Review Reports Versions Notes

Abstract

:
Antibiotic resistance is a major health problem worldwide, causing more deaths than diabetes and cancer. The dissemination of vertical and horizontal antibiotic resistance genes has been conducted for a selection of pan-resistant bacteria. Here, we test if the aerobic and anaerobic bacteria from human feces samples in health conditions are carriers of beta-lactamases genes. The samples were cultured in a brain–heart infusion medium and subcultured in blood agar in aerobic and anaerobic conditions for 24 h at 37 °C. The grown colonies were identified by their biochemical profiles. The DNA was extracted and purified by bacterial lysis using thermal shock and were used in the endpoint PCR and next generation sequencing to identify beta-lactamase genes expression (OXA, VIM, SHV, TEM, IMP, ROB, KPC, CMY, DHA, P, CFX, LAP, and BIL). The aerobic bacterias Aeromonas hydrophila, Citrobacter freundii, Proteus mirabilis, Providencia rettgeri, Serratia fonticola, Serratia liquefaciens, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Pantoea agglomerans, Enterococcus faecalis, and Enterobacter cloacae, the anaerobic bacteria: Capnocytophaga species, Bacteroides distasonis, Bifidobacterium adolescentis, Bacteroides ovatus, Bacteroides fragilis, Eubacterium species, Eubacterium aerofaciens, Peptostreptococcus anaerobius, Fusobacterium species, Bacteroides species, and Bacteroides vulgatus were isolated and identified. The results showed 49 strains resistant to beta-lactam with the expression of blaSHV (10.2%), blaTEM (100%), blaKPC (10.2%), blaCYM (14.3%), blaP (2%), blaCFX (8.2%), and blaBIL (6.1%). These data support the idea that the human enteric microbiota constitutes an important reservoir of genes for resistance to beta-lactamases and that such genes could be transferred to pathogenic bacteria.

1. Introduction

The indiscriminate and unconscious use of antibiotics in the clinic, agriculture, and livestock have been increased the selection pressure in the worldwide microbiome, inducing resistant, multiresistant, and pan-resistant pathogen bacteria selection [1,2,3]. This problem reached a maximal level during the last two years where the antibiotic use has increased drastically due to the pandemic spread of SARS-CoV-2, since more than 70% of COVID-19 patients have received complimentary treatment with antibiotics drugs [4,5].
Bacterial resistance to antibiotics is a situation that has been increasing during the last decades, converting into a wide world public health problem [6,7], that complicates the treatment of the infection while increases the mortality rate in both nosocomial or community-acquired infectious diseases [8,9]. This resistance is reaching a critical point, as the increase in these resistant, multi-resistant, and pan-resistant pathogenic strains causes serious medical complications [10].
The lactam groups of molecules are integrated into four families, i.e., beta-lactam [11], gamma-lactam [12], delta-lactam [13], and epsilon-lactam [14], with a specific action and not necessarily like antibiotics. Specifically, the beta-lactams drugs show antibiotic effects in a wide bacterial variety. They are characterized by a beta-lactam ring presence, which confers the antimicrobial effect by the transpeptidases and carboxypeptidases inactivation (the proteins responsible for the biosynthesis of the cell wall) through their binding to Penicillin Binding Protein (PBPs) receptors [15]. The beta-lactam family is made up of various members, such as penicillins B and G, amoxicillin, ampicillin, cephalosporins (cephalothin, cephalexin, ceftriaxone, and cefepime), carbapenems (imipenem, meropenem, ertapenem), aztreonbactam, monobactam, and some others. The indiscriminate and unconscious use of these antibiotics in daily clinical practice has caused an increase in multiresistant Enterobacteriaceae strains, especially Escherichia coli and Klebsiella pneumoniae, turning this situation into a serious global health problem [16]. During the last decade that there has been a significant increase in the presence of multi-resistant strains worldwide, mainly in the European Union. The European Read for Antimicrobial Resistance Surveillance (EARSNet) has been identified pan-resistant Escherichia coli and Klebsiella pneumoniae strains [17,18]. The bacteria have various resistance mechanisms, mainly associated with plasmid assimilation, which allow cross-resistance against a wide range of antibiotics [19]. The most widely described mechanism of antibiotic resistance that is mediated by plasmid transfer is the enzymatic degradation of the beta-lactam ring through the expression of beta-lactamases [20]. The genes encoding for the beta-lactamases enzymes have been widely spread among the bacterial population, through mobile genetic elements, which confer a plasmid-mediated multi-resistance [21,22]. These multi-resistance bacteria complicate the patient treatments and condition the type of antibiotics that can be administrated for the treatment of common infections [23]. The first-line antibiotic treatment regimens for gastrointestinal and airway infections usually include beta-lactams drugs, such as ampicillin, amoxicillin, or third generation cephalosporins (Ceftriaxone), but the resistance determines the treatment that can be given to patients and decreases the effectiveness significantly of these treatments. The Carbapenems (ertapenem, meropenem, imipenem) have been widely used as an alternative for the treatment of these resistant bacteria, however, in recent years, resistant bacteria strains to these antibiotics have been identified [24]. The main causes associated with this increase in bacterial resistance are the error in the medical prescription, self-medication, incomplete antibiotics treatment, and the use of these drugs by the agricultural and livestock industry for the treatment of crops for human consumption [25].
For these reasons, we test the hypothesis that the Enterobacteriaceae integrating the human gastrointestinal microbiome are carriers of beta-lactamases genes in healthy individuals who have not received antibiotic treatment during their last year of life.

2. Results

2.1. Bacteria Identification

From the sampling of 20 different medicine students in healthy conditions from Mexico City, 49 beta-lactam resistant strains were isolated, founding 27 strands of 12 different aerobic and 22 strand of 11 different anaerobic beta-lactam resistant Enterobacteriaceae species (Figure 1). The distribution of the identified bacteria was as follows. Aerobic: Aeromonas hydrophila 3.7% (n = 1), Citrobacter freundii 3.7% (n = 1), Enterobacter aerogenes 7.4% (n = 2), Enterococcus faecalis 14.8% (n = 4), Enterobacter cloacae 22.2% (n = 6), Escherichia coli 11.1% (n = 3), Klebsiella pneumoniae 11.1%% (n = 3), Proteus mirabilis 3.7% (n = 1), Providencia rettgeri 3.7% (n = 1), Pantoea agglomerans 11.1% (n = 3), Serratia fonticola 3.7% (n = 1), Serratia liquefaciens 3.7% (n = 1), Anaerobic: Bacteroides distasonis 4.5% (n = 1), Bifidobacterium adolescentis 4.5% (n = 1), Bacteroides ovatus 4.5% (n = 1), Bacteroides fragilis 4.5% (n = 1), Bacteroides species 13.6% (n = 3), Bacteroides vulgatus 18.2% (n = 4), Capnocytophaga species 4.5% (n = 1), Eubacterium species 4.5% (n = 1), Eubacterium aerofaciens 18.1% (n = 4), Fusobacterium species 13.6% (n = 3) and Peptostreptococcus anaerobius 9.1% (n = 1) (Figure 1). All these data were confirmed by whole DNA sequencing using NGS (Table 1), showing 98% of concordance with the automatized bacterial identification. All bacteria genomes size sequenced were similar to those reported in the gene bank, observing Δ from 1% to 8% of differences compared with the reported sizes (Table 2).

2.2. Antimicrobial Susceptibility Testing

The antimicrobial susceptibility test of beta lactam resistant bacteria showed, that the 88.9% (n = 24) showed resistance to amoxicillin/clavulanic acid, ampicillin, and vancomycin, followed by resistance to cefixime with 81.5% (n = 22). Resistance towards cefuroxime and towards cephalothin occurred in both cases in 70.4% (n = 19) of the isolated aerobic bacteria, followed by resistance towards cefazolin and cefaclor, both with 66.7% (n = 18). 63% (n = 17) of the aerobic bacteria isolates showed resistance to piperacillin, followed by resistance to doxycycline with 51.9% (n = 14) resistance. The lowest resistance was observed towards piperacillin/tazobactam 18.5% (n = 5), ceftizoxime 14.8% (n = 4) and towards meropenem and imipenem, both with 11.1% (n = 3), While 95.5% (n = 21) of the isolated anaerobic bacteria showed resistance towards vancomycin followed by resistance towards cefixime with 81.8% (n = 18) and towards piperacillin, cephalothin, cefaclor and cefuroxime, each with 72.7% (n = 18). 68.2% (n = 15) of this population was resistant to cefazolin, followed by resistance towards doxycycline 63.6% (n = 14) and towards Amoxicillin/Clavulanic acid and Ampicillin, both with 54.5% (n = 12) and towards Ceftizoxime 41.5% (n = 10). The lowest resistance was observed towards Piperacillin/Tazobactam 27.3% (n = 6) and to Meropenem and Imipenem, each with 4.5% (n = 1), and non-beta-lactam resistance is showed in Table 3.

2.3. Beta-Lactamases Gene Family Identification

The endpoint PCR results showed that 100 % of the obtained bacterial strain carries at least a gene of Beta-Lactamases, identified the gene families transcribed and the phenotype responsible for Beta-Lactam resistance: 49 strains were positive to blaTEM (100%), five positive strains for the blaSHV (10.2%), five positive strains for blaKPC (10.2%), seven positive strains for blaCYM (14.3%), one positive strain for blaP (2%), four positive strain for blaCFX (8.2%), and three positive strains for blaBIL (6.1%) gene families (Table 4). No members of gene families blaOXA, blaVIM, blaIMP, blaROB, blaCTX, blaDHA, and blaLAP were found in all obtained strains from feces of human and healthy conditions. These data were also confirmed by whole-genome sequencing of isolated strains (Table 3 and Table 4).
The isolated strains from human feces in healthy conditions showed a restricted pattern of resistance to beta-lactam drugs. The individual analysis showed that of the blaTEM was present in all (100% n = 49) of isolated strains, from these the 77.5% (n = 38) was carrier only for this gene family, the other 25.5% of isolated strains showed a mixed genotype for multiple gene families encoding beta-lactamase and specific for each strain, conformed from two (blaTEM + blaBIL, blaTEM + blaCYM, or blaTEM + blaP) to five (blaTEM + blaSHV + blaKPC + blaCYMX + blaDHA + blaBIL) gene families of beta-lactamases (Table 5).

2.4. Beta-Lactamases Genotype

The NGS sequencing showed seven members of the TEM beta-lactamases gene family including blaTEM-1, blaTEM-2, blaTEM-3, blaTEM-10, blaTEM-12, blaTEM-24, and blaTEM-52 distributed in the 49 blaTEM positive strains, two members of KPC beta-lactamases gene family (blaKPC-2 and blaKPC-3), only one member of each one of CYM (blaCMY-2), BIL (blaBIL-1), CFX (blaCTX-M-15), and P (blaP) beta-lactamases gene families were found (Table 4).
The mixed gene expression pattern was present some aerobic of Enterobacteriaceae species: Aeromonas hydrophila (blaTEM-1 + blaSHV-12 + blaBIL-1), Enterobacter aerogenes (blaTEM-1 + blaKPC-2), Enterococcus faecalis (blaTEM-1 + blaSHV-1), Enterobacter cloacae (blaTEM-12 + blaSHV-1), Escherichia coli (blaTEM-52 + blaSHV-12 + blaCMY-2 + blaCTX-M-15), Klebsiella pneumoniae (blaTEM-10 + blaSHV-12 + blaKPC-3 + blaCMY-2 + blaCTX-M-15), Proteus mirabilis (blaTEM-1 + blaKPC-2 + blaCMY-2 + blaCTX-M-15), Pantoea agglomerans (blaTEM-1 + blaCMY-2), Serratia fonticola (blaTEM-1 + blaKPC-2), while the anaerobic bacteria that express mixed genotype were: Bacteroides distasonis (blaTEM-1 + blaBIL-1), Bacteroides fragilis (blaTEM-2 + blaCMY-2), Bacteroides vulgatus (blaTEM-1 + blaCMY-2), and Fusobacterium species (blaTEM-12 + blaP). The NGS analyses for all the bacterial strains tested were negative to blaOXA, blaVIM, blaIMP, blaROB, blaCTX, blaDHA, and blaLAP (Table 6).

3. Discussion

The wide use of antibiotics in the clinic, agriculture, and livestock induce a high selection pressure in the worldwide microbiome allowing the resistant, multi-resistant, and pan-resistant bacteria selection and colonization of the gut of human and some other animals including insects and seafoodn [1,2,3]. In the same way, contamination affects vegetables for human consumption [26,27,28,29,30,31,32,33,34,35,36,37]. Even though many of these bacteria do not produce pathology, they are capable of transferring these antibiotic resistances mechanisms to human gut microbiota members and pathogenic bacteria, making it a reservoir for antibiotic resistance genes [37]. Following this idea, our research group characterized the beta-Lactam resistome carried by the aerobic and anaerobic Enterobacteriaceae from healthy medical students of Mexico City.

3.1. Enterobacteriaceae Characterization

The data analysis demonstrates the presence of multiple members of aerobic and anaerobic beta-lactam resistant Enterobacteriaceae, the identified bacteria distribution was as follows. Aerobic: Aeromonas hydrophila, Citrobacter freundii, Proteus mirabilis, Providencia rettgeri, Serratia fonticola, and Serratia liquefaciens. Each one represents 3.7% of all beta-lactam resistant aerobic Enterobacteriaceae, the Enterobacter aerogenes represent 7.4%, Enterococcus faecalis was present in 14.8%, Enterobacter cloacae were in the 22.2% of all isolated strands, the more abundant Enterobacteriaceae were Escherichia coli, Klebsiella pneumoniae in and Pantoea agglomerans were found in the 11.1% each one (Figure 1, Table 1 and Table 2). The founded species from human feces are in concordance with previous results were reported the repertoire and variations of human gut microbiota, they characterized 113 different bacteria, including Gram-positive bacteria (Bifidobacterium, Eubacterium, Peptostreptococcus, Ruminococcus, Lactobacillus, and Clostridium genera) and Gram-negative bacteria (Bacteroides, Fusobacteria genera) [38]. All our bacterial culture data were corroborated by NGS sequencing show 98% of concordance in the final bacterial identification. These data are supported by previously published works. Our NGS data are in concordance with other NGS studies that found 71% of all bacterial community was conformed by Firmicutes, 9% was Actinobacteria, while Bacteroidetes, Proteobacteria, and Cyanobacteria represent a relatively low abundance ranging from 3% to 7%, the bacterial families found were: Lactobacillacea, Ruminococcacea, Lancnospiraceacea, Clostridiaceacea. Streptococceacea, Streptophyta, Staphylococceacea, Verrucomicrobiaceace, and Enterobacteriaceae among others [39]. However, the composition of the intestinal microbiota varies depending on the type of diet [40]. The obtained results from feces samples reveal the potentially pathogenic enterobacteria presence in the human digestive tract in healthy conditions, their presence as the gastrointestinal resident microbiome, and not necessarily associated with an active gut infection. To determine the potential of these batteries to cause infection, it would be necessary to study other factors, such as virulence and pathogenesis genes expressed by each bacterium, bacterial load, and subjects’ immunological status.

3.2. Beta-Lactam Gene Families

Due to the isolated Enterobacteriaceae being isolated in presence of the beta-Lactam drug in the culture media (Table 2), all strains were expected to be carriers at least one member of the different gene families that code for beta-Lactamases. The endpoint PCR identified the gene families transcribed and the phenotype responsible for Beta-Lactam resistance: 100% of the isolated strain were positive to blaTEM, 10.2% positive for the blaSHV, 10.2% positive to blaKPC, 10.2% positive for blaCYM (14.3%), 2% positive to blaP, 8.2% positive to blaCFX and 6.1 positive blaBIL gene family (Table 3 and Table 4), no strand positives to members of blaOXA, blaVIM, blaIMP, blaROB, blaCTX, blaDHA, and blaLAP gene families were found (Table 3 and Table 4). These results accord with previous works, finding that Enterobacteriaceae expressed a member of blaCTX, blaSHV, and blaTEM genes families [41], while around the world the main reported beta-lactamase families in the multidrug-resistant Enterobacteriaceae are: blaKPC, blaTEM, blaOKP, blaOXA, blaSHV, blaVIM and blaNDM [42], in agreement with our results.

3.3. Beta-Lactam Phenotypes

The sequencing data shows that 83.7% of all resistant Enterobacteriaceae was a carrier of blaTEM gene family including blaTEM-1, blaTEM-2, blaTEM-10, blaTEM-12, blaTEM-24, and blaTEM-52 members, like a unique or multiple beta-lactam resistance mechanisms, for the blaSHV and blaKPC gene family we found only two members of each family including blaSHV-1, blaSHV-12, blaKPC-2 and blaKPC-3, while for families blaCMY, blaBIL, blaCTX, and blaP we only find a member of each one of them including blaCMY-2, blaBIL-1, blaCTX-M-15, and blaP-1, all of these beta-lactamases genes were found in combination with a member of the blaTEM gene family. In specific, we found that blaTEM-1 a non-xtended-spectrum beta-lactamase (ESBL) was dominant in unique beta-lactamase gene expression, while the 16.3% of all resistant Enterobacteriaceae was carrier of mixed phenotype with an ESBL, in specific in Aeromonas hydrophila (blaTEM-1 + blaSHV-12 + blaBIL-1), Enterobacter aerogenes (blaTEM-1 + blaKPC-2), Enterococcus faecalis (blaTEM-1 + blaSHV-1), Enterobacter cloacae (blaTEM-12 + blaSHV-1), Escherichia coli (blaTEM-52 + blaSHV-12 + blaCMY-2 + blaCTX-M-15), Klebsiella pneumoniae (blaTEM-10 + blaSHV-12 + blaKPC-3 + blaCMY-2 + blaCTX-M-15), Proteus mirabilis (blaTEM-1 + blaKPC-2 + blaCMY-2 + blaCTX-M-15), Pantoea agglomerans (blaTEM-1 + blaCMY-2), Serratia fonticola (blaTEM-1 + blaKPC-2), while the anaerobic bacteria that express mixed genotype were: Bacteroides distasonis (blaTEM-1 + blaBIL-1), Bacteroides fragilis (blaTEM-2 + blaCMY-2), Bacteroides vulgatus (blaTEM-1 + blaCMY-2) and Fusobacterium species (blaTEM-12 + blaP), in the NGS analysis, all bacterial strains tested were negative to blaOXA, blaVIM, blaIMP, blaROB, blaDHA and blaLAP (Table 5). These results are in agreement with a Korean report were they found that the blaTEM-1 is the most prevalent beta-lactamase expressed by the stool Enterobacteriaceae of healthy human [43]. In the same way, the Swiss study conducted with Enterobacteriaceae isolated from healthy humans found that the blaCTX-M-14 and blaCTX-M-15 are the most ESBL prevalent and are generally expressed as unique genes. Here, too, it is reported that blaTEM-1 + blaCTX-M1, blaTEM-1 + blaCTX-M-14 and blaTEM-1 + blaCTX-M-14 phenotypes are the most prevalent [44], in agreement with our results, which found that blaCTX-M-15 is always expressed in mixed genotype.
The bacterial isolates obtained were identified with simple or complex beta-lactam resistome. This is especially relevant since the resistance gene can be transmitted from among a wide range of Enterobacteriaceae through plasmid and mobile genetic elements, conferring antibiotic resistance to pathogenic bacteria that are causing gastrointestinal and systemic infection, complicating their treatment. These findings are especially important since the complex resistome expressed by the Enterobacteriaceae were integrated by one member of blaTEM gene family, including blaTEM-1, blaTEM-2, blaTEM-10, blaTEM-12, blaTEM-24, and blaTEM-52, unique or in combination one or more member of blaSHV, blaKPC, blaCMY, blaBIL, blaCTX, and blaP gen families, including blaSHV-1, blaSHV-12, blaKPC-2, blaKPC-3, blaCMY-2, blaBIL-1, blaCTX-M-15, or blaP-1 (Table 3 and Table 4), which confer resistance to ampicillin, penicillins including oxacillin, extended-spectrum cephalosporins (cefotaxime, ceftazidime), cephamycin, carbapenems, and monobactams characteristics that limit the therapeutic option of infections caused by bacterial carriers of these genes.
The data analysis showed multiple members of aerobic and anaerobic Enterobacteriaceae that show multi-resistance molecular mechanisms to beta-lactams drugs, mediated by unique resistance genes or conforming a beta-lactam resistome, in asymptomatic individuals. This can be widely explained by mechanisms such as antibiotics self-medication, abuse, and error in their medical prescription, as well as lack of adherence to antibiotic treatment, including via the consumption of contaminated water [45,46,47] or foods, mainly meats [48,49], fruits [50], and vegetables [26,51]. Moreover, the agriculture [52] and livestock industries [53,54] indiscriminately use the beta-lactam drugs to maximize production [55,56].

4. Materials and Methods

4.1. Bioinformatic Analysis and Primer Design

The bioinformatic analysis and primer design were previously described and reported by our research group [26]. Briefly, we obtained the beta-Lactamases integrons and DNA sequences from the GenBank of NCBI, all reported sequences of beta-lactamases we found were used to design primer for the PCR. The DNA sequence alignments were made with ClustalW v.2 software (http://www.clustal.org/clustal2/ accessed on 10 April 2021) [27,28,29], to obtain the phylogenetic trees by using FigTree V1.4.0 software (http://tree.bio.ed.ac.uk/software/figtree/ accessed 10 April 2021) [30]. The conserved sequences found in the alignment were used to design a set of specific and degenerate primers (PerPrimer v1.1.21 Software, http://perlprimer.sourceforge.net accessed 10 April 2021 [31] under astringent criteria, length (18–25 bp), Tm (60–62 °C), GC (40–60 %), ∆T° (1 °C), Amplicons (83–230 bp) [26].

4.2. Sampling

Twenty volunteers (10 men and 10 women) were selected for this study. All of them were medicine students from Mexico City enrolled at the Anahuac University, aged between 20 and 22 years, with no history of beta-lactam antibiotics treatment in the last year or have been suffering diarrhea during that period. Donors were provided with the sample collection material, which consisted of plastic containers, gloves, a cardboard paper sheet, and wooden spatulas; all the material was sterile. The donors were asked to deposit a portion of their stool on the cardboard sheet and from this, they collect with the wooden spatula, an approximate volume of 10 cubic cm, and place it in the sterile container. The time elapsed from when the sample was taken to its beginning of processing in the laboratory was not more than 2 h, this in order not to alter, as far as possible, the bacterial viability. Then, five g of each human feces samples were weighed and cultured in BHI (brain and heart infusion broth) (Becton Dickinson, Franklin Lakes, NJ) incubated at 37 °C for 24 h, in both aerobic and anaerobic conditions.

4.3. Bacterial Isolation

For the anaerobic conditions, the BHI tubes containing samples were immediately placed in the BD BBL ™ GasPak ™ anaerobic jar, one envelope of BD BBL ™ CO2 gas generators and another of BD BBL ™ GasPak ™ anaerobic indicator were placed on them. Later they were incubated at 37 °C during 24 h. For the aerobic conditions, the tubes with BHI containing the samples were directly incubated at 37 °C for 24 h. After is incubation, 10 μL from the BHI were taken, subcultured in MacConkey agar (Becton Dickinson, Franklin Lakes, NJ, USA), and incubated at 37 °C for 24 h. The obtained colonies were subcultured in blood agar and incubated at 37 °C for 24 h, in both aerobic or anaerobic conditions.

4.4. Biochemical Bacterial Identification

The automatized bacterial identification was made according to previously reported by our research group. Briefly, bacterial suspensions were made, by depositing two or three medium-sized colonies (2 to 3 mm) in BBL™ Crystal™ Inoculum Broth (Becton Dickinson, Franklin Lakes, NJ, USA). Said inoculum was adjusted to a Mac Farland 1.0 scale (Expected CFU/mL 3.0 × 108). The inoculum was deposited in BBL™ Crystal™ Enteric/Nonfermenter or Anaerobe ID Kit plates, incubated at 37 °C for 18 h, without CO2 and 40–60% humidity. Finally, the plates were read by the BBL™ Crystal™ AutoReader (Becton Dickinson, Franklin Lakes, NJ, USA) and the results were analyzed with the BBL™ Crystal™ MIND v.5.05 Software (Becton Dickinson, Franklin Lakes, NJ, USA) [26].

4.5. Antimicrobial Susceptibility Testing

The antimicrobial susceptibility testing was done following a previously reported method [26]. Briefly, the pure colonies obtained from blood agar were resuspended in bacterial suspensions, and were made depositing two or three medium-sized colonies (2 to 3 mm) in BBL Crystal Inoculum Broth (Becton Dickinson; Franklin Lakes, NJ, USA). The obtained inoculum was adjusted while using a Mac Farland 0.5 reading (Expected CFU/mL 1.5 × 108), and cultured in Müeller Hinton 150 × 15 mm2 media BD BBL (Becton Dickinson Franklin Lakes, NJ, USA). The antibiotic discs were applied with the Sensi-Disc Designer Dispenser System. The antibiotics panel was conformed by ampicillin (10 µg), ampicillin/sulbactam (10/10 µg), mezlocillin (75 µg), carbenicillin (100 µg), piperacillin/tazobactam (100/10 µg), cefazolin (30 µg), cefaclor (30 µg), cefepime (30 µg), cefoperazone (75 µg), and cefotetan (30 µg) from Becton Dickinson (Franklin Lakes, NJ, USA), Müeller Hinton medium were incubated at 37 °C for 24 h in both aerobic and anaerobic conditions. In anaerobic conditions, the media were placed in an anaerobic jar (BD BBL™ GasPak™), with a C02 gas generators envelope (BD BBL™) and another envelope of BD BBL™ GasPak™ anaerobic indicator placed on them.

4.6. DNA Extraction

4.6.1. Crude Extract

Five mL of Luria-Bertani broth (LB) were inoculated with an isolated bacterial colony and incubated overnight at 37 °C with continuous shaking (200 rpm), the bacterial culture was centrifuged at 4000 rpm for five minutes at room temperature, bacterial the pellet was resuspended on 1 mL of sterile free-RNAse and free-DNAse deionized water, the bacterial suspension was heated at 94 °C for 10 min followed by ice shock. Finally, the sample of lysed bacterial was kept at –80 °C until use [26].

4.6.2. Genomic DNA Extraction

The DNA extraction was done following a previously reported method [26]. Briefly, 500 µL of bacterial culture was obtained from a tested single bacterial colony for genomic DNA isolation by RTP pathogen kit (Invitek, Germany) following the manufacturer’s instruction. The eluted DNA solution was quantified by absorbance and its integrity was verify by 2% agarose gel electrophoresis. The sample was kept at –20 °C until use.

4.6.3. Plasmid DNA Extraction

The plasmid DNA extraction was done following a previously reported method [26], by using plasmid DNA isolation by using PureLink HiPure Plasmid DNA Purification Kit (Invitrogen, USA) following the manufacturer’s instructions. Plasmid DNA solution was quantified by digital spectrophotometry by using a NanoDrop spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA) and its integrity was verified by electrophoresis in 2 % agarose gel, the sample was kept at –20 °C until use.

4.7. Endpoint PCR

The endpoint PCR to identify the β-Lactamases gene families was made by using previously reported specific and degenerated primes (Table 7) [26]: Amplification was made in 25 μL of the reaction mixture containing 2.5 μL of 10x PCR buffer (100 mM TRIS•HCI, 15 mM MgCl2, and 500 mM KCl, pH 8.3), 200 nM each dNTP, 10 μM each primer, 1 U Taq DNA polymerase (Invitrogen; Carlsbad, CA, USA), and 2 μL of crude extract or 10 ng of DNA (genomic or plasmidic). The PCR conditions were 94 °C for 5 min, then 35 cycles of 94 °C for 30 s, 60 °C for 30 s, 72 °C for 30 s, and finally 72 °C for 10 min. The PCR products were analyzed by electrophoresis in a 2% Agarose gel prestained with ethidium bromide and the image was digitized in a GelLogistic 3000 photodocumenter.

4.8. Whole and Plasmid DNA Sequencing

The DNA sequencing was performed following a previously reported method by our research group [26], the indexed libraries that were prepared using a standard Illumina Nextera XT DNA Sample Preparation Kit (FC-131-1096) for small genomes and were sequenced on the MiSeq platform (Illumina; San Diego, CA, USA). Adapters and barcodes were trimmed by the default setting in the Illumina experiment manager, generating 300-bp paired-end reads. The quality of the unprocessed reads was assessed using FastQC High Throughput Sequence QC Report v:0.11.5 (Babraham Bioinformatics, Babraham Institute; Cambridge, UK) [32]. A minimum Q score of more than 30 for at least 85% of all reads was attained. All reads were mapped using BWA-MEM aligner version 0.7.7-r441 (Wellome trust, Sanger Institute, Hinxton, UK) [33] and SAMtools version 1.3.1 (Wellome trust, Sanger Institute, Hinxton, UK). The NOVO genome assembly was done using the SPAdes Genome Assembler software version 3.11 (CAB, St. Petersburg State University, St. Petersburg, Russia) [34]. The metagenomic analysis for the taxonomic classification of bacteria was done by using the software Kraken taxonomic sequence classification system Version 0.10.5-beta (CCB, Johns Hopkins University, Baltimore, MD, USA) [35]. The beta-lactamase genes were identified by the comparative analysis while using the Basic Local Alignment Search Tool (BLAST, NCBI-NIH, Bethesda, MD, USA) [36].

5. Conclusions

The human gut bacteriome is an important reservoir and mediator for the environmental beta-lactam resistome. The cumulative beta-lactam resistome in the Enterobacteriaceae is indicative of the indiscriminate and irrational use of beta-lactam drugs in practically all economical worldwide activities, especially in Mexico City. The gut bacteriome express beta-lactam resistome in healthy conditions is integrated by multiple beta-lactamases gen families, such as blaTEM, blaSHV, blaKPC, blaCYM, blaBIL, blaCFX, blaCYM, blaBIL, and blaP, which altogether confer resistant, multi-resistant, and pan-resistant characteristics against beta-lactam antibiotics.

Author Contributions

Conceptualization, R.V.-L. and J.A.G.-B.; methodology, D.A.Á.-H., J.A.G.-B.; software, M.L.-L.; validation, S.S.-G., C.P.-L., and J.A.G.-B.; formal analysis, R.V.-L., T.G.-G., and J.A.A.-A.; investigation, J.A.G.-B.; resources, J.A.G.-B.; data curation, R.V.-L., E.G.-C., and S.S.-G.; writing original draft preparation, R.V.-L.; writing review and editing, J.A.G.-B.; project administration, R.V.-L., and J.A.G.-B.; funding acquisition, J.A.G.-B. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the National Council for Science and Technology (CONACYT) Mexico through the Sectoral Fund for Research in Health and Social Security (FOSISS), grant MOD.ORD./2012/SSA/IMSS/ISSSTE-CONACYT/000000000181384 “and it was also supported by CICSA of Faculty of Health Sciences of the Universidad Anáhuac México Project Number 201917.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of the Facultad de Ciencias de la Salud Universidad Anáhuac Mexico Campus Norte and of the “1 October” Regional Hospital, ISSSTE, approval code E015-591 (13 January 2018).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data presented in this study are available from the corresponding author.

Acknowledgments

The authors thankfully acknowledge to María Goti Rodríguez (Principal of Hospital Regional “Primero de Octubre”) and Jose Damian Carrillo Ruiz director of the Faculty of Health Sciences, Antonio Ibarra Coordinator of CICSA, and José Pozón Director of Academic Vice-rectory Research, all of them for their support in the development of part of this research by the Universidad Anáhuac México.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Kardas, P.; Devine, S.; Golembesky, A.; Roberts, C. A systematic review and meta-analysis of misuse of antibiotic therapies in the community. Int. J. Antimicrob. Agents 2005, 26, 106–113. [Google Scholar] [CrossRef]
  2. Kadima, M.G. Concurrent Use of Traditional Medicine and Prescribed Antibiotics and/or Antiviral Medicines and Their Effects on Antimicrobial Resistance and Treatment Failure in Ilembe District, Kwazulu-Natal Province, South Africa. Master’s Thesis, University of KwaZulu-Natal, Scottsville, Pietermaritzburg, South Africa, January 2019. [Google Scholar]
  3. Huttner, A.; Harbarth, S.; Carlet, J.; Cosgrove, S.; Goossens, H.; Holmes, A.; Jarlier, V.; Voss, A.; Pittet, D. Antimicrobial resistance: A global view from the 2013 World Healthcare-Associated Infections Forum. Antimicrob. Resist. Infect. Control 2013, 2, 31. [Google Scholar] [CrossRef] [Green Version]
  4. Lucien, M.A.B.; Canarie, M.F.; Kilgore, P.E.; Jean-Denis, G.; Fénélon, N.; Pierre, M.; Cerpa, M.; Joseph, G.A.; Maki, G.; Zervos, M.J.; et al. Antibiotics and antimicrobial resistance in the COVID-19 era: Perspective from resource-limited settings. Int. J. Infect. Dis. 2021, 104, 250–254. [Google Scholar] [CrossRef] [PubMed]
  5. Chen, Z.; Guo, J.; Jiang, Y.; Shao, Y. High concentration and high dose of disinfectants and antibiotics used during the COVID-19 pandemic threaten human health. Environ. Sci. Eur. 2021, 33, 1–14. [Google Scholar] [CrossRef] [PubMed]
  6. Bush, K.; Bradford, P.A. Epidemiology of β-lactamase-producing pathogens. Clin. Microbiol. Rev. 2020, 33, e00047-19. [Google Scholar] [CrossRef] [PubMed]
  7. Rivera-Tapia, J.A. Antibiotic resistance, public health problem. An. Med. Asoc. Med. Hosp. ABC 2003, 48, 42–47. [Google Scholar]
  8. Kang, C.-I.; Kim, S.-H.; Park, W.B.; Lee, K.-D.; Kim, H.-B.; Kim, E.-C.; Oh, M.-D.; Choe, K.W. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: Risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob. Agents Chemother. 2005, 49, 760–766. [Google Scholar] [CrossRef] [Green Version]
  9. Zilberberg, M.D.; Shorr, A.F.; Micek, S.T.; Vazquez-Guillamet, C.; Kollef, M.H. Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: A retrospective cohort study. Crit. Care 2014, 18, 596. [Google Scholar] [CrossRef] [PubMed]
  10. Fodor, A.; Abate, B.A.; Deák, P.; Fodor, L.; Gyenge, E.; Klein, M.G.; Koncz, Z.; Muvevi, J.; Ötvös, L.; Székely, G.; et al. Multidrug Resistance (MDR) and Collateral Sensitivity in Bacteria, with Special Attention to Genetic and Evolutionary Aspects and to the Perspectives of Antimicrobial Peptides—A Review. Pathogens 2020, 9, 522. [Google Scholar] [CrossRef]
  11. Kong, K.-F.; Schneper, L.; Mathee, K. Beta-lactam antibiotics: From antibiosis to resistance and bacteriology. APMIS 2010, 118, 1–36. [Google Scholar] [CrossRef] [Green Version]
  12. Caruano, J.; Muccioli, G.G.; Robiette, R. Biologically active γ-lactams: Synthesis and natural sources. Org. Biomol. Chem. 2016, 14, 10134–10156. [Google Scholar] [CrossRef] [PubMed]
  13. Lee, E.; Lim, D.Y.; Lee, K.A. Synthesis of A δ-Lactam Analogue of Penem Carboxylate. Bull. Korean Chem. Soc. 1990, 11, 361–362. [Google Scholar]
  14. Dutton, F.E.; Lee, B.H. Epsilon-lactam analogs of the anthelmintic cyclodepsipeptide PF1022A. Tetrahedron Lett. 1998, 39, 5313–5316. [Google Scholar] [CrossRef]
  15. Heesemann, J. Resistenzmechanismen gegen Betalaktamantibiotika. Infection 1993, 21, S4–S9. [Google Scholar] [CrossRef]
  16. Mathers, A.J.; Peirano, G.; Pitout, J.D.D. The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae. Clin. Microbiol. Rev. 2015, 28, 565–591. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. Coque, T.M.; Baquero, F.; Cantón, R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Eurosurveillance 2008, 13, 19044. [Google Scholar] [CrossRef] [PubMed]
  18. Vatopoulos, A. High rates of metallo-beta-lactamase-producing Klebsiella pneumoniae in Greece—A review of the current evidence. Eurosurveillance 2008, 13, 7–8. [Google Scholar] [CrossRef]
  19. Brolund, A.; Sandegren, L. Characterization of ESBL disseminating plasmids. Infect. Dis. 2015, 48, 18–25. [Google Scholar] [CrossRef]
  20. De Angelis, G.; Del Giacomo, P.; Posteraro, B.; Sanguinetti, M.; Tumbarello, M. Molecular mechanisms, epidemiology, and clinical importance of β-lactam resistance in enterobacteriaceae. Int. J. Mol. Sci. 2020, 21, 5090. [Google Scholar] [CrossRef] [PubMed]
  21. Schultsz, C.; Geerlings, S. Plasmid-mediated resistance in enterobacteriaceae: Changing landscape and implications for therapy. Drugs 2012, 72, 1–16. [Google Scholar] [CrossRef] [PubMed]
  22. El Salabi, A.; Walsh, T.R.; Chouchani, C. Extended spectrum β-lactamases, carbapenemases and mobile genetic elements responsible for antibiotics resistance in Gram-negative bacteria. Crit. Rev. Microbiol. 2013, 39, 113–122. [Google Scholar] [CrossRef]
  23. Perez, F.; El Chakhtoura, N.G.; Papp-Wallace, K.M.; Wilson, B.M.; Bonomo, R.A. Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: Can we apply “precision medicine” to antimicrobial chemotherapy? Expert Opin. Pharm. 2016, 17, 761–781. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Codjoe, F.S.; Donkor, E.S. Carbapenem Resistance: A Review. Med. Sci. 2017, 6, 1. [Google Scholar] [CrossRef] [Green Version]
  25. Mills, M.C.; Lee, J. The threat of carbapenem-resistant bacteria in the environment: Evidence of widespread contamination of reservoirs at a global scale. Environ. Pollut. 2019, 255, 113143. [Google Scholar] [CrossRef] [PubMed]
  26. Vázquez-López, R.; Solano-Gálvez, S.; León-Chávez, B.A.; Thompson-Bonilla, M.R.; Guerrero-González, T.; Gómez-Conde, E.; Martínez-Fong, D.; González-Barrios, J.A. Characterization of gene families encoding beta-lactamases of gram-negative rods isolated from ready-to-eat vegetables in Mexico City. High. Throughput 2018, 7, 36. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Lauretti, L.; Riccio, M.L.; Mazzariol, A.; Cornaglia, G.; Amicosante, G.; Fontana, R.; Rossolini, G.M. Cloning and characterization of bla(VIM), a new integron-borne metallo- β-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob. Agents Chemother. 1999, 43, 1584–1590. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. de M. Rangel, W.; de Oliveira Longatti, S.M.; Ferreira, P.A.A.; Bonaldi, D.S.; Guimarães, A.A.; Thijs, S.; Weyens, N.; Vangronsveld, J.; Moreira, F.M.S. Leguminosae native nodulating bacteria from a gold mine As-contaminated soil: Multi-resistance to trace elements, and possible role in plant growth and mineral nutrition. Int. J. Phytoremediation 2017, 19, 925–936. [Google Scholar] [CrossRef]
  29. Sievert, D.M.; Ricks, P.; Edwards, J.R.; Schneider, A.; Patel, J.; Srinivasan, A.; Kallen, A.; Limbago, B.; Fridkin, S. National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infect. Control Hosp. Epidemiol. 2013, 34, 1–14. [Google Scholar] [CrossRef]
  30. Centers for Disease Control and Prevention Vital Signs: Carbapenem-Resistant Enterobacteriaceae. Available online: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6209a3.htm (accessed on 12 April 2021).
  31. Ye, Q.; Wu, Q.; Zhang, S.; Zhang, J.; Yang, G.; Wang, J.; Xue, L.; Chen, M. Characterization of extended-spectrum β-lactamase-producing Enterobacteriaceae from retail food in China. Front. Microbiol. 2018, 9, 1709. [Google Scholar] [CrossRef]
  32. Babraham Bioinformatics—FastQC Babraham Bioinformatics—FastQC A Quality Control tool for High Throughput Sequence Data. Available online: https://www.bioinformatics.babraham.ac.uk/projects/fastqc/ (accessed on 12 April 2021).
  33. Burrows-Wheeler Aligner Burrows-Wheeler Aligner / [Bio-bwa-help] Citing bwa-mem. Available online: https://sourceforge.net/p/bio-bwa/mailman/message/30894287/ (accessed on 12 April 2021).
  34. CodonCode Corporation Sequence Assembly and Alignment with CodonCode Aligner. Available online: https://www.codoncode.com/aligner/ (accessed on 12 April 2021).
  35. System, K.T.S.C. Kraken Taxonomic Sequence Classification System. Available online: https://ccb.jhu.edu/software/kraken/ (accessed on 12 April 2021).
  36. BLAST BLAST: Basic Local Alignment Search Tool. Available online: https://blast.ncbi.nlm.nih.gov/Blast.cgi (accessed on 12 April 2021).
  37. Hu, Y.; Yang, X.; Qin, J.; Lu, N.; Cheng, G.; Wu, N.; Pan, Y.; Li, J.; Zhu, L.; Wang, X.; et al. Metagenome-wide analysis of antibiotic resistance genes in a large cohort of human gut microbiota. Nat. Commun. 2013, 4, 2151. [Google Scholar] [CrossRef] [Green Version]
  38. Lagier, J.C.; Million, M.; Hugon, P.; Armougom, F.; Raoult, D. Human gut microbiota: Repertoire and variations. Front. Cell. Infect. Microbiol. 2012, 2, 136. [Google Scholar] [CrossRef] [Green Version]
  39. Parma, L.; Candela, M.; Soverini, M.; Turroni, S.; Consolandi, C.; Brigidi, P.; Mandrioli, L.; Sirri, R.; Fontanillas, R.; Gatta, P.P.; et al. Next-generation sequencing characterization of the gut bacterial community of gilthead sea bream (Sparus aurata, L.) fed low fishmeal based diets with increasing soybean meal levels. Anim. Feed Sci. Technol. 2016, 222, 204–216. [Google Scholar] [CrossRef]
  40. Tidjani Alou, M.; Lagier, J.-C.; Raoult, D. Diet influence on the gut microbiota and dysbiosis related to nutritional disorders. Hum. Microbiome J. 2016, 1, 3–11. [Google Scholar] [CrossRef] [Green Version]
  41. Korzeniewska, E.; Harnisz, M. Beta-lactamase-producing Enterobacteriaceae in hospital effluents. J. Environ. Manag. 2013, 123, 1–7. [Google Scholar] [CrossRef]
  42. Bush, K. Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. Curr. Opin. Microbiol. 2010, 13, 558–564. [Google Scholar] [CrossRef]
  43. Joo, E.-J.; Kim, S.J.; Baek, M.; Choi, Y.; Seo, J.; Yeom, J.-S.; Ko, K.S. Fecal carriage of antimicrobial-resistant enterobacteriaceae in healthy Korean adults. J. Microbiol. Biotechnol. 2018, 28, 1178–1184. [Google Scholar] [CrossRef]
  44. Geser, N.; Stephan, R.; Korczak, B.M.; Beutin, L.; Hächler, H. Molecular identification of extended-spectrum-β-lactamase genes from Enterobacteriaceae isolated from healthy human carriers in Switzerland. Antimicrob. Agents Chemother. 2012, 56, 1609–1612. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Cacace, D.; Fatta-Kassinos, D.; Manaia, C.M.; Cytryn, E.; Kreuzinger, N.; Rizzo, L.; Karaolia, P.; Schwartz, T.; Alexander, J.; Merlin, C.; et al. Antibiotic resistance genes in treated wastewater and in the receiving water bodies: A pan-European survey of urban settings. Water Res. 2019, 162, 320–330. [Google Scholar] [CrossRef] [PubMed]
  46. Adesoji, A.T.; Ogunjobi, A.A. Detection of Extended Spectrum Beta-Lactamases Resistance Genes among Bacteria Isolated from Selected Drinking Water Distribution Channels in Southwestern Nigeria. Biomed. Res. Int. 2016, 2016, 7149295. [Google Scholar] [CrossRef] [Green Version]
  47. Delgado-Gardea, M.C.E.; Tamez-Guerra, P.; Gomez-Flores, R.; de la Serna, F.J.Z.-D.; Eroza-de la Vega, G.; Nevárez-Moorillón, G.V.; Pérez-Recoder, M.C.; Sánchez-Ramírez, B.; González-Horta, M.D.C.; Infante-Ramírez, R. Multidrug-resistant bacteria isolated from surface water in Bassaseachic Falls National Park, Mexico. Int. J. Environ. Res. Public Health 2016, 13, 597. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Trott, D. β-lactam Resistance in Gram-negative Pathogens Isolated from Animals. Curr. Pharm. Des. 2012, 19, 239–249. [Google Scholar] [CrossRef]
  49. Chen, C.-M.; Ke, S.-C.; Li, C.-R.; Wu, Y.-C.; Chen, T.-H.; Lai, C.-H.; Wu, X.-X.; Wu, L.-T. High Diversity of Antimicrobial Resistance Genes, Class 1 Integrons, and Genotypes of Multidrug-Resistant Escherichia coli in Beef Carcasses. Microb. Drug Resist. 2017, 23, 915–924. [Google Scholar] [CrossRef]
  50. Heaton, J.C.; Jones, K. Microbial contamination of fruit and vegetables and the behaviour of enteropathogens in the phyllosphere: A review. J. Appl. Microbiol. 2008, 104, 613–626. [Google Scholar] [CrossRef]
  51. Gudda, F.O.; Waigi, M.G.; Odinga, E.S.; Yang, B.; Carter, L.; Gao, Y. Antibiotic-contaminated wastewater irrigated vegetables pose resistance selection risks to the gut microbiome. Environ. Pollut. 2020, 264, 114752. [Google Scholar] [CrossRef]
  52. Iwu, C.D.; Korsten, L.; Okoh, A.I. The incidence of antibiotic resistance within and beyond the agricultural ecosystem: A concern for public health. Microbiologyopen 2020, 9, e1035. [Google Scholar] [CrossRef] [PubMed]
  53. Tekiner, İ.H.; Özpınar, H. Occurrence and characteristics of extended spectrum beta-lactamases-producing enterobacteriaceae from foods of animal origin. Braz. J. Microbiol. 2016, 47, 444–451. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Mesa, R.J.; Blanc, V.; Blanch, A.R.; Cortés, P.; González, J.J.; Lavilla, S.; Miró, E.; Muniesa, M.; Saco, M.; Tórtola, M.T.; et al. Extended-spectrum β-lactamase-producing Enterobacteriaceae in different environments (humans, food, animal farms and sewage). J. Antimicrob. Chemother. 2006, 58, 211–215. [Google Scholar] [CrossRef] [Green Version]
  55. Ruppé, E.; Andremont, A.; Armand-Lefèvre, L. Digestive tract colonization by multidrug-resistant Enterobacteriaceae in travellers: An update. Travel Med. Infect. Dis. 2018, 21, 28–35. [Google Scholar] [CrossRef] [PubMed]
  56. Armand-Lefèvre, L.; Andremont, A.; Ruppé, E. Travel and acquisition of multidrug-resistant Enterobacteriaceae. Med. Mal. Infect. 2018, 48, 431–441. [Google Scholar] [CrossRef] [PubMed]
Pharmaceuticals 14 00533 g001 550
Figure 1. Bacterial frequency. The graph shows the frequency of beta-Lactam resistant aerobic and anaerobic Enterobacteriaceae isolated from feces sample of medicine student in healthy conditions.
Figure 1. Bacterial frequency. The graph shows the frequency of beta-Lactam resistant aerobic and anaerobic Enterobacteriaceae isolated from feces sample of medicine student in healthy conditions.
Pharmaceuticals 14 00533 g001
Table
Table 1. Metagenomic identification of the aerobic and anaerobic beta-lactam resistant bacteria isolated from feces cultures of humans in healthy conditions.
Table 1. Metagenomic identification of the aerobic and anaerobic beta-lactam resistant bacteria isolated from feces cultures of humans in healthy conditions.
BacteriaTotal ReadsClassified ReadsDomainPhylumClassOrderFamilyGenusSpecies
Aerobic
Aeromonas hydrophila4,502,8974,412,839 (98%)4,103,940 (93%)3,734,586 (91%)3,211,744 (86%)2,697,865(84%)2,212,249 (82%)1,791,922 (81%)1,361,861 (76%)
Citrobacter freundii1,816,4301,798,266 (99%)1,744,318 (97%)1,657,102 (95%)1,491,392 (90%)1, 327,339(89%)1,101,691 (83%)870,336 (79%)539,608 (62%)
Enterobacter aerogenes897,648727,095 (81%)567,134 (78%)436,693 (77%)331,887 (76%)248,915 (75%)1817,08 (73%)130,830 (72%)91,581 (70%)
Enterococcus faecalis3,134,8723,040,826 (97%)2,852,734 (91%)2,821,385 (90%)2,695,990 (86%)2,664,641 (85%)2,539,246 (81%)2,507,898 (80%)2,476,549 (79%)
Enterobacter cloacae945,761898,473 (95%)892,798 (94%)871,046 (92%)866,317 (91%)850,239 (89%)842,673 (89%)836,998 (85%)835,107 (88%)
Escherichia coli2,361,8272,078,408 (88%)1,936,698 (82%)1,865,843 (79%)1,606,042 (68%)1,511,569 (64%)1,464,333 (62%)1,440,714 (61%)1,393,478 (59%)
Klebsiella pneumoniae1,129,6751,039,301 (92%)1,016,708 (90%)1,005,411 (89%)994,114 (88%)915,037 (81%)881,147 (78%)869,850 (77%)835,960 (74%)
Proteus mirabilis816,524808,359 (99%)805,909 (98%)803,460 (97%)767,533 (94%)751,202 (92%)743,037 (91%)738,954 (90%)726,706 (89%)
Providencia rettgeri354,869273,249 (77%)266,152 (75%)259,054 (73%)255,506 (72%)237,762 (67%)223,567 (63%)216,470 (61%)191,629 (54%)
Pantoea agglomerans497,802438,066 (88%)433,088 (87%)408,198 (82%)393,264 (79%)388,286 (78%)353,439 (71%)338,505 (68%)333,527 (67%)
Serratia fonticola1,347,9641,334,484 (99%)1,267,086 (94%)1,253,607 (93%)1,226,647 (91%)1,186,208 (88%)1,145,769 (85%)1,132,290 (84%)997,493 (74%)
Serratia liquefaciens256,789190,024 (74%)182,320 (71%)179,752 (70%)174,617 (68%)159,209 (62%)156,641 (61%)154,073 (60%)133,530 (52%)
Anaerobic
Bacteroides distasonis845,168752,201 (89%)726,844 (86%)718,393 (85%)693,038 (82%)667,683 (79%)659,231 (78%)625,424 (74%)608,521 (72%)
Bifidobacterium adolescentis748,751718,801 (96%)715,806 (95%)704,575 (94%)700,082 (93%)689,600 (92%)687,353 (91%)682,861 (91%)658,901 (88%)
Bacteroides ovatus965,743905,867 (94%)902,004 (94%)898,141 (93%)893,312 (92%)888,484 (91%)830,539 (86%)743,622 (77%)637,390 (66%)
Bacteroides fragilis986,241976,379 (99%)966,516 (98%)956,654 (97%)951,723 (96.4%)946,791 (96.1%)927,067 (94.3%)917,204 (93%)915,232 (92.6%)
Bacteroides species567,284486,162 (85.7%)483,893 (85.3%)482,759 (85.1%)481,624 (84.9%)478,788 (84.4%)478,220 (84.3%)477,086 (84.1%)474,817 (83.7%)
Bacteroides vulgatus928,712911,995 (98.2%)911,066 (98.1%)833,055 (89.7%)830,269 (89.4%)828,411 (89.2%)825,625 (88.9%)819,124 (88.2%)816,338 (87.9%)
Capnocytophaga species349,817319,733 (91%)315,535 (90.2%)313,471 (89.6%)312,911 (89.4%)312,282 (89.2%)312,212 (89.1%)299,793 (85.7%)295,211 (84.3%)
Eubacterium species567,492542,522 (95.6%)541,387 (95.4%)540,309 (95.2%)539,685 (95.1%)537,982 (94.8%)536,280 (94.5%)535,712 (94.4%)534,010 (94.1%)
Eubacterium aerofaciens814,927620,974 (76.2%)616,085 (75.5%)604,676 (74.2%)599,786 (73.6%)595,712 (73.1%)594,082 (72.9%)581,043 (71.3%)576,968 (70.8%)
Fusobacterium species237,491204,717 (86.2%)203,292 (85.6%)192,843 (81.2%)191,418 (80.6%)189,755 (79.9%)187,855 (79.1%)186,193 (78.4%)185,955 (78.3%)
Peptostreptococcus anaerobius729,358686,691 (94.1%)686,399 (94.1%)683,044 (93.6%)682,314 (93.5%)679,251 (93.1%)677,282 (92.8%)612,442 (83.9%)587,498 (80.5%)
Table
Table 2. Whole-genome sequencing characteristics of aerobic and anaerobic Enterobacteriaceae rods isolated from human feces in healthy conditions.
Table 2. Whole-genome sequencing characteristics of aerobic and anaerobic Enterobacteriaceae rods isolated from human feces in healthy conditions.
BacteriaCDSNumber of Sequence ContigsGenome Size (bp)
AssembledReportedDifference
Aerobic
Aeromonas hydrophila4,4281,1245,124,4874,911,246213,241
Citrobacter freundii5,0647895,343,9525,297,05246,900
Enterobacter aerogenes4,5451,4845,578,7245,280,350298,374
Enterococcus faecalis2,9699513,111,0173,038,91472,103
Enterobacter cloacae4,5451,4844,982,1764,772,910209,266
Escherichia coli5,7041,5615,689,1565,615,38973,767
Klebsiella pneumoniae5,0715835,479,1735,315,120164,053
Proteus mirabilis3,7725844,183,8694,209,44525,576
Providencia rettgeri4,4976384,954,3264,780,676173,650
Pantoea agglomerans4,2557384,090,2204,047,71242,508
Serratia fonticola5,9459166,483,0436,000,511482,532
Serratia liquefaciens4,9364955,706,9875,395,544311,443
Anaerobic
Bacteroides distasonis3,8966034,952,3234,812,038140,285
Bifidobacterium adolescentis1,7424182,173,7202,089,64584,075
Bacteroides ovatus4,8037566,425,2676,472,48947,222
Bacteroides fragilis4,1001,0255,188,9675,474,541285,574
Bacteroides species2,4019042,658,6242,628,34530,279
Bacteroides vulgatus5,0554065,311,4545,681,290369,836
Capnocytophaga species2,2085022,614,5272,837,214222,687
Eubacterium species2,1975052,628,8032,450,450178,353
Eubacterium aerofaciens1,8871,5482,128,7542,264,854136,100
Fusobacterium species2,1137382,159,7992,185,89726,098
Peptostreptococcus anaerobius1,7938471,989,7532,106,123116,370
Table
Table 3. Whole antibiograms characteristics of beta-lactam resistant bacteria isolated from feces cultures of humans in healthy conditions.
Table 3. Whole antibiograms characteristics of beta-lactam resistant bacteria isolated from feces cultures of humans in healthy conditions.
Antibiotic FamiliesDrugsAerobicsAnaerobic
Frequency%Frequency%
Beta-LactamAmoxicillin/Clavulanic acid (AmC-30)2488.91254.5
Piperacillin (PIP-100)1763.01672.7
Piperacillin/Tazobactam (TZP-110)518.5627.3
Doxycycline (D-30)1451.91463.6
Ampicillin 10(AM-10)2488.91254.5
Cephalothin 1° (CF-30)1970.41672.7
Cefazolin 1° (CZ-30)1866.71568.2
Cefaclor 2° (CEC-30)1866.71672.7
Cefuroxime 2° (CXM-30)1970.41672.7
Cefixime 3° (CFM-5)2281.51881.8
Ceftizoxime 3a (ZOX-30)414.81045.5
Meropenem (MEM-10)311.114.5
Imipenem (IPM-10)311.114.5
Table
Table 4. Frequency of beta-lactamase gene families identified by endpoint PCR in roads cultured from gut microbiota in healthy conditions.
Table 4. Frequency of beta-lactamase gene families identified by endpoint PCR in roads cultured from gut microbiota in healthy conditions.
Gene FamilyPositive Strains (n)%Gene FamilyPositive Strains (n)%
blaTEM49100.0blaBIL36.1
blaSHV510.2blaP12.0
blaKPC510.2blaCFX48.2
blaCYM714.3
Table
Table 5. Beta-Lactamases (bla) gene families carried by the aerobic and anaerobic Enterobacteria of humans in healthy conditions.
Table 5. Beta-Lactamases (bla) gene families carried by the aerobic and anaerobic Enterobacteria of humans in healthy conditions.
Aerobic BacteriaBeta-Lactamases FamiliesAnaerobic BacteriaBeta-Lactamases Families
TEMSHVKPCCYMBILCFXTEMCYMBILP
Aeromonas hydrophila++ + Capnocytophaga species+
Citrobacter freundii+ Bacteroides distasonis+ +
Proteus mirabilis+ ++ +Bifidobacterium adolescenti+
Providencia rettgeri+ Bacteroides ovatus+
Serratia fonticola+ + Bacteroides fragilis++
Serratia liquefaciens+ Eubacterium species+
Enterobacter aerogenes+ + Eubacterium aerofaciens+
Escherichia coli++ + +Peptostreptocuccus anaerobius+
Klebsiella pneumoniae++++ +Fusobacterium species+ +
Pantoea agglomerans+ + Bacteroides vulgatus++
Enterococcus faecalis++ Bacteroides species+
Enterobacter cloacae++++ +
(+) Positive for the beta-lactamase gene family.
Table
Table 6. Mixed Genotype of the beta-lactam antibiotic resistome identified by next-generation sequencing in the aerobic and anaerobic Enterobacteria from feces of humans in healthy conditions.
Table 6. Mixed Genotype of the beta-lactam antibiotic resistome identified by next-generation sequencing in the aerobic and anaerobic Enterobacteria from feces of humans in healthy conditions.
BacteriaPhenotype of Beta-Lactamases
TEMSHVKPCCYMBILCFXP
Aerobic
Aeromonas hydrophilablaTEM-1blaSHV-12 blaBIL-1
Citrobacter freundiiblaTEM-2
Enterobacter aerogenesblaTEM-1 blaKPC-2
Enterococcus faecalisblaTEM-1blaSHV-1
Enterobacter cloacaeblaTEM-12blaSHV-1
Escherichia coliblaTEM-52blaSHV-12 blaCMY-2 blaCTX-M-15
Klebsiella pneumoniaeblaTEM-10blaSHV-12blaKPC-3blaCMY-2 blaCTX-M-15
Proteus mirabilisblaTEM-1 blaKPC-2blaCMY-2 blaCTX-M-15
Providencia rettgeriblaTEM-24
Pantoea agglomeransblaTEM-1 blaCMY-2
Serratia fonticolablaTEM-1 blaKPC-2
Serratia liquefaciensblaTEM-12
Anaerobic
Bacteroides distasonisblaTEM-1 blaBIL-1
Bifidobacterium adolescentisblaTEM-1
Bacteroides ovatusblaTEM-1
Bacteroides fragilisblaTEM-2 blaCMY-2
Bacteroides speciesblaTEM-1
Bacteroides vulgatusblaTEM-1 blaCMY-2
Capnocytophaga speciesblaTEM-1
Eubacterium speciesblaTEM-1
Eubacterium aerofaciensblaTEM-1
Fusobacterium speciesblaTEM-12 blaP-1
Peptostreptococcus anaerobiusblaTEM-1
Table
Table 7. Primers sequences and amplicon size for beta-lactamase gene family [26].
Table 7. Primers sequences and amplicon size for beta-lactamase gene family [26].
Gene FamilyPrimer NamePrimer Sequence (5’ to 3’)Tm (°C)PositionAmplicon (bp)
blaOXABlaOXA-FWGGTTTCGGTAATGCTGAAATTGG61.18214–236114
BlaOXA-RWGCTGTGTATGTGCTAATTGGGA61.19327–306
blaVIMBlaVIM-FWCGACAGTCARCGAAATTCC61.39105–123133
BlaVIM-RWCAATGGTCTSATTGTCCGTG61.34238–219
blaSHVBlaSHV-FW1CGTAGGCATGATAGAAATGGATC61.04133–155106
BlaSHV-RW1CGCAGAGCACTACTTTAAAGG61.33239–218
BlaSHV-FW2GCCTCATTCAGTTCCGTTTC61.62399–418141
BlaSHV-RW2CCATTACCATGAGCGATAACAG61.22540–518
blaTEMBlaTEM-FWGCCAACTTACTTCTGACAACG61.801699–1719213
BlaTEM-RWCGTTTGGAATGGCTTCATTC60.131912–1892
blaIMPBlaIMP-FW1GGAATAGARTGGCTTAAYTCTCG60.92319–332183
BlaIMP-RW1CYASTASGTTATCTKGAGTGTG62.45502–480
BlaIMP-FW2GGTGGAATAGARTGGCTTAAYTC61.11316–339192
BlaIMP-RW2CCAAACCACTACGTTATCTKGAG61.29508–485
blaROBBlaROB-FWCCAACATCGTGGAAAGTGTAG61.27718–739126
BlaROB-RWGTAAATTGCGTACTCATGATTGC60.90844–821
blaKPCBlaKPC-FWGCTAAACTCGAACAGGACTTTG61.79100–121117
BlaKPC-RWCTTGAATGAGCTGCACAGTG61.90216–197
blaCTXBlaCTX-FW1GATACCGCAGATAATACGCAG60.79161–181116
BlaCTX-RW1CGTTTTGCGTTTCACTCTG60.28276–258
BlaCTX-FW2GCTGATTCTGGTCACTTACTTC61.02789–81083
BlaCTX-RW2CGCCGACGCTAATACATC60.69855–872
BlaCTX-FW3CTGCTTAACTACAATCCSATTGC62.17314–336226
BlaCTX-RW3GGAATGGCGGTATTKAGC60.86539–522
blaCMYBlaCMY-FW1GTTTGAGCTAGGATCGGTTAG60.25337–357123
BlaCMY-RW1CTGTTTGCCTGTCAGTTCTG61.48460–441
BlaCMY-FW2GAACGAAGGCTACGTAGCT61.71213–231160
BlaCMY-RW2CTGAAACGTGATTCGATCATCA61.08372–351
blaDHABlaDHA-FW1GCATATTGATCTGCATATCTCCAC61.60399–422200
BlaDHA-RW1GCTGCTGTAACTGTTCTGC61.62598–580
BlaDHA-FW2GCGGATCTGCTGAATTTCTATC61.54464–485147
BlaDHA-RW2GCAGTCAGCAACTGCTCATAC61.05610–591
BlaDHA-FW3GTAAGATTCCGCATCAAGCTG61.74430–450117
BlaDHA-RW3GGGTTATCTCACACCTTTATTACTG61.08546–522
blaPBlaP-FWGGAGAATATTGGGATTACAATGGC61.74271–294204
BlaP-RWCGCATCATCGAGTGTGATTG61.80474–455
blaCFXBlaCFX-FWCCAGTCATATCATTGACAGTGAG60.86437–459177
BlaCFX-RWGACATTTCCTCTTCCGTATAAGC61.16613–591
blaLAPBlaLAP-FWAGGGCTTGAACAACTTGAAC61.07249–268126
BlaLAP-RWGTAATGGCAGCATTGCATAAC60.59374–354
blaBILBlaBIL-FWGCCGATATCGTTAATCGCAC61.65100–119128
BlaBIL-RWGTTATTGGCGATATCGGCTTTA60.98227–206
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Vázquez-López, R.; Solano-Gálvez, S.; Álvarez-Hernández, D.A.; Ascencio-Aragón, J.A.; Gómez-Conde, E.; Piña-Leyva, C.; Lara-Lozano, M.; Guerrero-González, T.; González-Barrios, J.A. The Beta-Lactam Resistome Expressed by Aerobic and Anaerobic Bacteria Isolated from Human Feces of Healthy Donors. Pharmaceuticals 2021, 14, 533. https://doi.org/10.3390/ph14060533

AMA Style

Vázquez-López R, Solano-Gálvez S, Álvarez-Hernández DA, Ascencio-Aragón JA, Gómez-Conde E, Piña-Leyva C, Lara-Lozano M, Guerrero-González T, González-Barrios JA. The Beta-Lactam Resistome Expressed by Aerobic and Anaerobic Bacteria Isolated from Human Feces of Healthy Donors. Pharmaceuticals. 2021; 14(6):533. https://doi.org/10.3390/ph14060533

Chicago/Turabian Style

Vázquez-López, Rosalino, Sandra Solano-Gálvez, Diego Abelardo Álvarez-Hernández, Jorge Alberto Ascencio-Aragón, Eduardo Gómez-Conde, Celia Piña-Leyva, Manuel Lara-Lozano, Tayde Guerrero-González, and Juan Antonio González-Barrios. 2021. "The Beta-Lactam Resistome Expressed by Aerobic and Anaerobic Bacteria Isolated from Human Feces of Healthy Donors" Pharmaceuticals 14, no. 6: 533. https://doi.org/10.3390/ph14060533

APA Style

Vázquez-López, R., Solano-Gálvez, S., Álvarez-Hernández, D. A., Ascencio-Aragón, J. A., Gómez-Conde, E., Piña-Leyva, C., Lara-Lozano, M., Guerrero-González, T., & González-Barrios, J. A. (2021). The Beta-Lactam Resistome Expressed by Aerobic and Anaerobic Bacteria Isolated from Human Feces of Healthy Donors. Pharmaceuticals, 14(6), 533. https://doi.org/10.3390/ph14060533

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop